Thursday, October 10, 2013

#MERS #Coronavirus Saudi Arabia Announces Absense of Virus among Pilgrims

Mecca, 10/10/2013 (AFP) - The Saudi Health Minister Abdullah Al-Rabiah not record any injury Corona virus among pilgrims who start next Sunday pilgrimage.
Al-Riyadh newspaper quoted Rabiah as saying that the health status of pilgrims "reassuring as it is not registered any case of epidemic or Mahgria including the Corona virus."
He stressed that "the ministry is very keen to follow up on the epidemiological situation in the countries of the world, in coordination with the World Health Organization and put crack down this year with a virus Corona, and give workers strict instructions to isolate any suspected case out and conduct the necessary tests to ensure their safety."
Rabiah said that there is a team of 600 employees of the ministry in the King Abdul Aziz Airport provide curative and preventive services in full coordination with the parties participating in the pilgrimage all.
And puts workers at Jeddah airport masks for Okabh of the Corona virus, which killed 58 victims in the world so far, including 49 in Saudi Arabia, where he appeared for the first time.
The World Health Organization announced last Friday that the number of people infected with the virus of 136 people, including 117 in Saudi Arabia.
And overshadowed by fears of the spread of Corona during the pilgrimage season, the largest religious gathering of Muslims in the world.
However, the Minister of Health was expressed optimism gap in the pilgrimage season of the virus in the absence of any registration injury Umrah season.
But he called the elderly, the infirm and people with chronic illnesses to avoid coming to the pilgrimage this year.



Wednesday, October 9, 2013

#MERS #Coronavirus Saudi Arabia MOH Update 10/9/13

October 9, 2013
Translation

 
In the framework of the epidemiological investigation and ongoing follow-up carried out by the Ministry of Health for HIV (Corona) new syndrome that causes 
Middle East of MERS-CoV respiratory ministry announces the registration of two cases in the Riyadh region.
First of a citizen at the age of 78 years old, suffers from several chronic diseases, has died of God's mercy. 
The second case to another citizen at the age of 55 years old and suffering from chronic diseases, has died God's mercy. 
http://www.moh.gov.sa/CoronaNew/PressReleases/Pages/mediastatemenet-2013-10-09-001.aspx

Monday, October 7, 2013

Pandemic Preparedness: Taking Our Cue From The Experts

A very good read full of resources, from Avian Flu Diary:

http://afludiary.blogspot.com/2013/10/pandemic-preparedness-taking-our-cue.html

ProMED: CHINA, H7N9 LOW TRANSMISSION POTENTIAL

Published Date: 2013-10-05 13:28:47
Subject: PRO/AH> Avian influenza, human (118): China, H7N9 low transmission potential
Archive Number: 20131005.1982621

Date: Wed 2 Oct 2013
Source: University of Minnesota Center for Infectious Disease Research and Policy (CIDRAP) [edited]
http://www.cidrap.umn.edu/news-perspective/2013/10/flu-scan-oct-02-2013


Researchers who used a sophisticated modeling approach incorporating H7N9 case data from China found hints that the virus has low transmission potential and that the pace of infection slowed in April [2013] after officials closed live-bird markets. The study, published in BMC Medicine today [2 Oct 2013], was conducted by a team from the National Institutes of Health, Arizona State University, and George Washington University.

The investigators used a Bayesian modeling technique [see http://en.wikipedia.org/wiki/Bayesian_statistics] to assess if the outbreak had a reproduction (R) number consistent with unsustained human transmission and if interventions reduced transmission. They compared their estimates with other zoonotic pathogens, including H5N1 avian influenza, variant H3N2 (H3N2v) influenza flu, and Nipah virus. Based on 130 lab-confirmed cases reported in China from March through 20 May 2013, their analysis found that transmission was low in Shanghai and Zhejiang province, and at 0.6 the R was well below the 1.0 level needed to sustain transmission. Researchers also found that the growth rate slowed in mid April [2013], which coincided with the closure of live-bird markets in large Chinese cities in early April. Compared with other zoonotic threats, the transmission threat from H7N9 was lower.

The authors said that, although the findings were based on a small number of cases and need to be confirmed, the modeling technique could be useful for measuring outbreak progression and the impact of control measures in the months ahead and provides a tool for monitoring pandemic potential in near real-time.

--
Communicated by:
ProMED-mail
<promed@promedmail.org>

[The reference for the BMC Medicine paper is: Transmission potential of influenza A/H7N9, February to May 2013, China; by Gerardo Chowell, Lone Simonsen, Sherry Towers, Mark A Miller and Cecile Viboud; in BMC Medicine 2013, 11:214 doi:10.1186/1741-7015-11-214; http://www.biomedcentral.com/1741-7015/11/214/abstract. The Abstract follows.

"Background: On 31 Mar 2013, the 1st human infections with the novel influenza A/H7N9 virus were reported in Eastern China. The outbreak expanded rapidly in geographic scope and size, with a total of 132 laboratory-confirmed cases reported by 3 Jun 2013, in 10 Chinese provinces and Taiwan [imported from mainland China]. The incidence of A/H7N9 cases has stalled in recent weeks, presumably as a consequence of live bird market closures in the most heavily affected areas. Here we compare the transmission potential of influenza A/H7N9 with that of other emerging pathogens and evaluate the impact of intervention measures in an effort to guide pandemic preparedness.

Methods: We used a Bayesian approach combined with a SEIR (Susceptible-Exposed-Infectious-Removed) transmission model fitted to daily case data to assess the reproduction number (R) of A/H7N9 by province and to evaluate the impact of live bird market closures in April and May 2013. Simulation studies helped quantify the performance of our approach in the context of an emerging pathogen, where human-to-human transmission is limited and most cases arises from spillover events. We also used alternative approaches to estimate R based on individual-level information on prior exposure and compared the transmission potential of influenza A/H7N9 with that of other recent zoonoses.

Results: Estimates of R for the A/H7N9 outbreak were below the epidemic threshold required for sustained human-to-human transmission and remained near 0.1 throughout the study period, with broad 95 percent credible intervals by the Bayesian method (0.01 to 0.49). The Bayesian estimation approach was dominated by the prior distribution, however, due to relatively little information contained in the case data. We observe a statistically significant deceleration in growth rate after 6 Apr 2013, which is consistent with a reduction in A/H7N9 transmission associated with the preemptive closure of live bird markets. Although confidence intervals are broad, the estimated transmission potential of A/H7N9 appears lower than that of recent zoonotic threats, including avian influenza A/H5N1, swine influenza H3N2sw and Nipah virus.

Conclusion: Although uncertainty remains high in R estimates for H7N9 due to limited epidemiological information, all available evidence points to a low transmission potential. Continued monitoring of the transmission potential of A/H7N9 is critical in the coming months as intervention measures may be relaxed and seasonal factors could promote disease transmission in colder months."

This analysis is consistent with independent studies, and a resurgence of disease should not occur unless there is some significant modification of the genetic properties of the H7N9 virus, or relaxation of the restrictions introduced to control access to poultry markets. - Mod.CP]

http://www.promedmail.org/direct.php?id=20131005.1982621

Thursday, October 3, 2013

#MERS #Coronavirus Saudi Arabia MOH Update October 1, 2013

October 1, 2013
In the framework of the epidemiological investigation and ongoing follow-up carried out by the Ministry of Health for HIV (Corona) that causes respiratory syndrome Middle East MERS-CoV. Ministry announces the registration of three cases of HIV infection in Riyadh.

First of a citizen at the age of 79 years is suffering from several chronic diseases, and Mkhalt of confirmed cases, and receives the necessary attention, and the second for citizenship at the age of 14 years, mixing with a confirmed case, too, and experiencing symptoms of a simple and health status is stable. The third is a citizen at the age of 45 years, Mkhalt to a confirmed case, suffering from chronic diseases, and receiving intensive care treatment. We ask God for their speedy recovery.

http://www.moh.gov.sa/CoronaNew/PressReleases/Pages/mediastatement-2013-10-01-001.aspx

Monday, September 30, 2013

Chinese CDC Issues Autumn Flu Warning

September 30, 2013

The Chinese Center for Disease Control and Prevention (China CDC) on Sunday warned of the likelihood that flu may spread from November.

The spread of the flu virus will peak in December and January, it forecast, adding that human migration and gathering in the upcoming week-long National Day holiday can also cause a spread of the virus.

The China CDC advised that precautions be taken, especially by schools, kindergartens, senior care homes, pregnant women, the elderly, infants and patients with chronic diseases.

The health watchdog suggested people lead a healthy lifestyle, enhance immunity and ensure ventilation in order to prevent flu and other respiratory diseases.
Vaccination is the most effective method to guard against flu, it added, suggesting pregnant women, seniors, babies, sufferers of chronic diseases and medical staff be vaccinated so as to enhance immunity.

Meanwhile, there have been no reports of human infection by H7N9 bird flu in the last two months, according to the CDC.

H7N9 cases in China reached 134 by the end of August, with the latest reported patient in south China's Guangdong Province, and the number of deaths to the virus stands at 45, it said, adding that infections have been recorded in 12 provinces and municipalities.

The CDC said it would be prepared for the virus' possible spreading in autumn and winter.
 
http://en.ce.cn/National/Local/201309/30/t20130930_1570892.shtml 

Sunday, September 29, 2013

WHO recommendation on influenza A(H7N9) vaccine virus

September 26, 2013
Since 31 March 2013, public health authorities in China have reported a total of 135 human cases of novel avian influenza A(H7N9) infection, including 44 deaths1. To date, there has been no evidence of sustained human-to-human transmission.
Because the A(H7N9) virus seems to transmit from animals to humans more readily than the highly pathogenic avian influenza A(H5N1) viruses, and little or no immunity against the novel virus A(H7N9) exists in the human population, WHO is actively working with its Member States and partners on effective responses and preparedness. As part of these efforts, candidate vaccine viruses2 are being developed and made available by the WHO GISRS.

To date, the HA sequences of 123 A(H7N9) viruses (54 viruses from 44 human cases and 69 avian/environmental viruses ) have been deposited in genetic sequence databases. Genetic analysis of the HA genes indicated limited heterogeneity among these viruses (see Figure). Antigenic analyses of 45 viruses from humans, animals and environment with post-infection ferret antisera indicated that the provisionally recommended vaccine virus, A/Anhui/1/2013- like virus3, elicits antibodies that react well with all viruses tested (see Table).

Based on genetic and antigenic analysis, it is recommended that:
- An A/Anhui/1/2013-like* virus be used for the development of influenza A(H7N9) vaccines for pandemic preparedness purposes.
* A/Shanghai/2/2013 is an A/Anhui/1/2013-like virus.

Status updates on the development and availability of influenza A(H7N9) candidate vaccine viruses4, as well as biosafety requirements5 on handling the A(H7N9) candidate vaccine viruses, are available on the WHO website.
The A(H7N9) viruses, including candidate vaccine viruses, are considered PIP Biological Materials and are being shared under the PIP Framework.6
For more information, please contact gisrs-whohq@who.int.

Continued:  http://www.who.int/influenza/human_animal_interface/influenza_h7n9/201309_h7n9_recommendation.pdf

Saturday, September 28, 2013

St. Louis Video Interview with Dr. Sharon Frey on Vaccine Work with #H7N9

 Video with Dr. Sharon Frey at link below

ST. LOUIS (KSDK) - There's a new flu pandemic brewing called H7N9. The first people to come down with it live in China, but the race to develop a vaccine is going on fast and furious right here in St. Louis.
You may be wondering how alarmed should you be, and how can you help, which is why we invited Dr. Sharon Frey to join First @ 4 Wednesday.
Dr. Frey is professor of infectious diseases at Saint Louis University School of Medicine and is heading up the work to find a vaccine.
Click the video player above to learn about how dangerous this strain of the flu is, and if it's a threat to St. Louisans.
If you'd like to volunteer for the study, call 314-977-6333 or e-mail vaccine@slu.edu  to find out more.

http://www.ksdk.com/news/article/399551/183/SLU-professor-heading-up-research-on-H7N9-vaccine

Government recruits volunteers for experimental bird flu vaccine

Excerpt - Editing is mine
September 27, 2013

Health officials are calling for 1,700 volunteers to enroll in a study of an experimental vaccine to fight bird flu (H7N9 avian influenza), according to the National Institutes of Health (NIH).

-snip-

So far, reports of H7N9 are primarily in China. According the NIH, the virus does not easily jump from person-to-person.
However, the health agency is concerned that the virus could mutate into a more problematic virus.

"H7N9 avian influenza virus...has the potential to cause widespread sickness and mortality," said Director Anthony S. Fauci, M.D at the National Institute of Allergy and Infectious Diseases (NIAID), a department of the NIH.

"We are now testing a vaccine candidate with and without adjuvant in an effort to prepare for and, hopefully, protect against this possibility."

-snip-

The study is comprised of two separate clinical trials. Together, the trials will enroll 1,700 healthy adults between the ages of 19 and 64 years old. A panel of independent experts will monitor safety throughout the trial, according to the NIH.
The H7N9 clinical trials are designed to gather information about:
  • safety of the candidate vaccine
  • immune responses at different doses
  • effects of adjuvants
Two different adjuvants will be tested along with the H7N9 vaccine itself. Those adjuvants include:
The H7N9 clinical trials will be conducted in the following cities:
  • Houston, Texas
  • Cincinnati, Ohio
  • Durham, North Carolina
  • Atlanta, Georgia
  • Seattle, Washington
  • Saint Louis, Missouri
  • Iowa City, Iowa
  • Baltimore, Maryland
  • Nashville, Tennessee




http://www.examiner.com/article/government-recruits-volunteers-for-experimental-bird-flu-vaccine

VVRP receives contract from NIH to continue its work as Vaccine & Treatment Evaluation Units

Excerpt - editing is mine
September 27, 2013

The Vanderbilt Vaccine Research Program (VVRP) has received a contract from the National Institutes of Health (NIH) to continue its work as one of the nation's Vaccine and Treatment Evaluation Units (VTEU). Vanderbilt is one of nine institutions that have the potential to receive funding up to $135 million per year from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, over a seven-year period.

"This contract renewal is evidence of the importance of this work to public health on an international and national scale," said Kathryn Edwards, M.D., Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics, and director of the VVRP.

-snip-

As a VTEU for the NIH, the VVRP has conducted trials to inform public policy twice in the last decade to address potential pandemic concerns: once to test and evaluate the H1N1 influenza vaccine at the start of the 2009 pandemic, and again just this month to evaluate a vaccine against a potential future pandemic threat from the H7N9 avian influenza.

Other research projects involve the testing of enhancements to the formulation of influenza vaccines to improve their protective power. The additives that are used to enhance flu vaccine are called "adjuvants."

"When these adjuvants are added to vaccines, they improve the responses and reduce the amount of vaccine needed," Edwards said. "This has proven to be particularly important in avian influenza vaccines which can lack the ability to adequately stimulate a protective response in our immune systems."

Edwards says adjuvants are also exciting because of their potential to help avoid vaccine shortages in the future. If an adjuvant makes a vaccine 20 times more potent, it allows manufacturers to stretch vaccine supplies into 20 times more doses.

"That might mean, in the case of pandemic flu, that we can protect our population and others in developing countries that do not have the potential to make vaccines," Edwards said.


http://www.news-medical.net/news/20130927/VVRP-receives-contract-from-NIH-to-continue-its-work-as-Vaccine-and-Treatment-Evaluation-Units.aspx

Friday, September 27, 2013

#MERS #Coronavirus Saudi Arabia MOH Update 27 September 2013

[3 Cases in ICU from Riyadh. Global Total: 136. Saudi Arabia: 111]

27 September 2013
In the framework of the epidemiological investigation and ongoing follow-up carried out by the Ministry of Health for HIV (Corona) The new strain of the Middle East respiratory syndrome MERS-CoV Ministry announces the registration of three cases of HIV infection in Riyadh. First of citizenship at the age of 78 years suffer from several chronic diseases and receive intensive care treatment. And the second for citizenship at the age of 53 years old, suffers from health problems and is currently also receive intensive care treatment. The third is a citizen at the age of 63 years old, suffering from chronic diseases as well, and receive intensive care treatment praying to God for their speedy recovery.

http://tinyurl.com/m4yk8r6

#MERS #Coronavirus Case Fatality Rate = 45% .. 26% possible nosocomial transmissions -Eurosurveillance

Published Date: 2013-09-26 23:48:22
Subject: PRO/AH/EDR> MERS-CoV - Eastern Mediterranean (73): global reviews
Archive Number: 20130926.1969696

Excerpt:

[1] Global review - Eurosurveillance
Date: 26 Sep 2013
Source: Eurosurveillance 2013: 18(39), Article 3 [edited]
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20596

Of 129 cases with available information on transmission, 33 (26 percent) were possible nosocomial transmissions, 15 of these cases were healthcare workers (HCW). 17 of the 23 cases reported as HCW were female.

The overall CFR among the 133 cases is 45 percent on [25 Sep 2013]. Among symptomatic cases the CFR decreased from 23 of 40 cases (58 percent) in March to May to 21 of 77 (27 percent) in June to September 2013.

http://www.promedmail.org/direct.php?id=20130926.1969696

Duke Medicine Selected as New Site for Competitive Vaccine and Treatment Research Program

[excerpt - editing below is mine]

September 26, 2013
DURHAM, N.C. -- Duke Medicine has been named a Vaccine and Treatment Evaluation Unit (VTEU) by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to evaluate vaccines, treatments and diagnostics to protect people from infectious diseases, including emerging public health needs.

Duke was the only new site named since 2007 to the existing group of eight VTEUs. Each institution has the potential to receive funding estimated to be up to $135 million annually over a seven-year period.

-snip-

Established in 1962, the VTEUs have been instrumental in the development of new vaccines, including the infant pneumococcal vaccine. They have also tested innovative ways to deliver protection from infectious diseases, including a nasal spray alternative to the flu shot. VTEUs are also beginning to play a growing role in testing treatments for viral infections and improving diagnostic tools.

A key strength of VTEUs is their ability to enroll large numbers of participants in clinical trials to rapidly test vaccines in public health emergencies such as pandemic flu. Researchers can quickly gather and share information on vaccine safety and effectiveness, which is critical during pandemic situations.


http://www.dukehealth.org/health_library/news/duke-medicine-selected-as-new-site-for-competitive-vaccine-and-treatment-research-program

Malaysia: TH Medical Team Ready For MERS Threat


MAKKAH, Sept 27 (Bernama) -- The Pilgrims Fund Board (Tabung Haji) health and medical teams here and in Medina are ready to face the Novel corona virus or Middle East Respiratory Syndrome Corona virus (MERS-CoV) pandemic.

Malaysian Haj Delegation (Medical) deputy head Dr Mohamad Faid Abdul Rashid said the Tabung Haji teams were well-equipped to handle the situation, in the event of an epidemic.

However, he said, no case of the disease had been reported, adding that most Malaysian pilgrims sought medical treatment for lung infection, breathing difficulties and normal cough.

He said 23 Malaysian pilgrims were warded at the three Tabung Haji medical centres. They comprised 15 in Makkah (at Syisya and Aziziah) and eight at Al Addin in Madinah.

All were reported to be in stable condition, Dr Mohamad Faid told reporters here today.

http://www.bernama.com/bernama/v7/ge/newsgeneral.php?id=981145

NIH renews funding for University of Maryland vaccine research

[Excerpt - editing below is mine]

Public release date: 26-Sep-2013
Contact: Bill Seiler
bseiler@umm.edu
410-328-8919
University of Maryland Medical Center 


Baltimore, MD - September 26, 2013 - The University of Maryland School of Medicine's Center for Vaccine Development (CVD) has successfully competed for and received a renewed contract to conduct basic research and clinical studies of vaccines, diagnostics, and therapeutics. Support for this work to combat existing and emerging infectious diseases is provided by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). 
-snip-
According to Dr. Kotloff, the NIAID expanded its required scope of expertise to qualify as a VTEU for this most recent contract competition. "Future projects are likely to use molecular tools that are now available to design better vaccines and to unmask signals that lead to immunity, while avoiding side effects," she says. As a result, the CVD team has augmented its multidisciplinary collaboration with colleagues at the University of Maryland Institute for Genome Sciences and the School of Pharmacy, both located on the University of Maryland campus in Baltimore.

The new VTEU contract has more emphasis on international studies, compared with previous contracts.

"This emphasis on global health is a great match for the CVD because our center has a large geographic reach to facilitate clinical studies in several African and Asian countries as well as Santiago, Chile," says E. Albert Reece, M.D., Ph.D., M.B.A., vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the University of Maryland School of Medicine. "The Center's domestic and international staff includes experts in a variety of fields, ranging from molecular biology and immunology, to internal medicine and pediatrics, to epidemiology and biostatistics, positioning the School of Medicine to contribute significantly to the development and testing of novel vaccines and novel vaccine delivery systems."
-snip-

A strength of the VTEUs is their ability to rapidly enroll large numbers of volunteers into trials. This rapid-response capability is especially important for testing vaccines designed to counteract emerging public health concerns, such as the vaccine against the 2009 H1N1 influenza virus, which has become a component of the seasonal flu vaccine. Earlier this month, the VTEUs launched a national, multi-center trial of a vaccine aimed to prevent an especially virulent avian influenza virus, H7N9, which emerged in people early in 2013.

http://www.eurekalert.org/pub_releases/2013-09/uomm-nrf092613.php 

Thursday, September 26, 2013

China: Experts: Be alert of #H7N9 amid flu seasons

Excerpt - editing is mine

2013-09-26
BEIJING, Sept. 26 (Xinhuanet) -- The avian influenza strain of H7N9 is highly likely to return and affect humans in the autumn and winter on the Chinese mainland, warned Zeng Guang, chief epidemiologist at the Chinese Center for Disease Control and Prevention.
China has remained free of new human H7N9 cases for more than a month since the last fatality — a 51-year-old woman who died of multiple organ failure caused by the virus on Aug 12 in Huizhou, Guangdong province — according to the National Health and Family Planning Commission.
The woman, who was transferred from Langfang, Hebei province, in mid July, worked in slaughtering poultry at a local market.
China has reported 134 human infections of H7N9 on the mainland, including 45 deaths, official statistics show.
"Given that the virus never stopped circulating among birds, humans are also at risk of infection, particularly in the common peak flu season, which usually lasts till spring,"Zeng said.
An overlap of the peak flu season and more frequent smoggy weather could make the situation even worse and intervention efforts more complicated, he said.
Flu prevention requires good ventilation, which can't be easily supplied in smoggy weather, he explained.
He urged the public to take precautions such as to avoid staying in public places for long and to be aware of good personal hygiene, including frequent hand-washing.
In addition, to prevent H7N9 infection, "people shouldn't go to live poultry markets", he said.
Feng Zijian, director of the health emergency center of China CDC, echoed the need for public awareness but dismissed the possibility of a widespread human outbreak.
Close surveillance of the virus has so far detected no major mutations that would enable H7N9 to easily spread among humans, he said.
"We'll have joint consultation on Friday with the agriculture departments which oversee virus surveillance of animals to evaluate the epidemic risk in the autumn and winter season to guide more targeted interventions,"he said.
The Beijing Health Bureau said on Monday it would further strengthen surveillance and intervention of H7N9 in autumn and winter.
All districts and counties of the capital must give all patients with flu or flu-like symptoms within the jurisdiction H7N9 virus screening upon detection of any human bird flu case, according to an announcement by the bureau.

Continued:  http://news.xinhuanet.com/english/china/2013-09/26/c_132751003.htm

Flu Researcher Ron Fouchier Loses Legal Fight Over H5N1 Studies

September 25, 2013
Excerpt:

Virologist Ron Fouchier has suffered a loss in a legal battle with the Dutch government over the publication of his controversial H5N1 influenza research. On Friday, a Dutch district court ruled that the government was right to ask Fouchier to obtain an export license before sending two hotly debated papers out for publication. The ruling, published yesterday (Dutch), could provide new roadblocks for Fouchier’s research in the future.
At issue is Fouchier’s hotly debated paper showing that a few mutations can make H5N1, a virus that normally infects birds, transmissible through the air between ferrets, which was published in Science in June 2012. The fight also involved an accompanying paper published in the same issue in which Fouchier and others tried to gauge the likelihood that such viruses arise spontaneously in nature.

Continued:  http://news.sciencemag.org/health/2013/09/flu-researcher-ron-fouchier-loses-legal-fight-over-h5n1-studies

Food and Water Needs: Preparing for a Disaster or Emergency

From the CDC

Follow these steps to make sure you and your family have enough safe food and water (for drinking, cooking, bathing, etc.) available in the event of a disaster or emergency.

 

Wednesday, September 25, 2013

WHO Statement on the Third Meeting of the IHR Emergency Committee concerning MERS-CoV 25 Sept. 2013

WHO Statement
25 September 2013


The third meeting of the Emergency Committee convened by the Director-General under the International Health Regulations (2005) [IHR (2005)] was held by teleconference on Wednesday, 25 September 2013, from 12:00 to 14:30 Geneva time (CET).
During the informational session, Kingdom of Saudi Arabia and Qatar presented on recent developments in their countries. The WHO Secretariat provided an update on epidemiological developments, Hajj and Umrah and recent WHO activities related to MERS-CoV. The Committee reviewed and deliberated on the information provided.
The Committee concluded that it saw no reason to change its advice to the Director-General. Based on the current information, and using a risk-assessment approach, it was the unanimous decision of the Committee that the conditions for a Public Health Emergency of International Concern (PHEIC) have not at present been met.
While not considering the events to constitute a PHEIC, Members of the Committee reiterated their prior advice for consideration by WHO and Member States and emphasized the importance of:
  • strengthening surveillance, especially in countries with pilgrims participating in Umrah and the Hajj;
  • continuing to increase awareness and effective risk communication concerning MERS-CoV, including with pilgrims;
  • supporting countries that are particularly vulnerable, especially in Sub-Saharan Africa taking into account the regional challenges;
  • increasing relevant diagnostic testing capacities;
  • continuing with investigative work, including identifying the source of the virus and relevant exposures through case control studies and other research; and
  • timely sharing of information in accordance with the International Health Regulations (2005) and ongoing active coordination with WHO.
The WHO Secretariat will continue to provide regular updates to the Members, and currently anticipates reconvening the Committee in late November 2013. Any serious new developments may require re-convening the Committee before then. Based on these views and the currently available information, the Director-General accepted the Committee’s assessment and thanked its Members for their advice.

1 The names and summary biographies of the Advisor and the Emergency Committee Members are available below.

For more information contact

Gregory Härtl
WHO Spokesperson
Coordinator, News, Social Media and Monitoring
Department of Communications
WHO, Geneva
Mobile: +41 79 203 6715
E-mail: hartlg@who.int


http://www.who.int/mediacentre/news/statements/2013/mers_cov_20130925/en/index.html 

Saudi Efforts to Stop MERS Virus Faulted

From the Wall Street Journal
Editing below is mine

September 24, 2013
By ELLEN KNICKMEYER in Hafr al Batin, Saudi Arabia, and BETSY MCKAY in Atlanta

Experts Still Don't Know How People Are Exposed to Mysterious Disease
Excerpt:

But in Hafr al Batin, a remote town in Saudi Arabia's northeast, relatives of four recent victims complained that no one in the family had ever heard warnings about the new disease or how to avoid catching it. "We had no idea," said Jawal al-Sahly, who lost his 39-year-old brother Fahd al-Sahly, their mother and two other family members.
Hospital workers in the town—site of 11 confirmed cases—kept telling Fahd that "he's not sick, 'You're making a big deal out of nothing,' " Mr. Sahly said in an interview, sitting on the faded carpet of the majlis, or meeting room, of the family's home. Authorities "don't want people to know there is corona in Saudi Arabia," he charged, using the name used by Saudis.

Complete Article: http://online.wsj.com/article/SB10001424127887324807704579086821158272430.html